[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cardiomyopathy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cardiomyopathy":30},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,26,0,25,[9,52,77,109,131,157,187,222,248,270,301,323,356,378,402,428,464,486,513,537,562,588,608,635,658],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":33,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":4,"leadSponsor":48,"locationsCount":51},"100143838","characterization-of-patients-with-uncommon-presentations-andor-uncommon-diseases-associated-with-the-cardiovascular-system-100143838",false,"NCT01143454","Characterization of Patients With Uncommon Presentations and\u002For Uncommon Diseases Associated With the Cardiovascular System","Cardiovascular Disease Discovery Protocol","* INCLUSION CRITERIA:\n\nEligible subjects may include anyone over 1 year of age who is affected with diseases\u002Fdisorders (index cases), or who is a relative of a person who is affected with diseases\u002Fdisorders. Relatives may include genetic carriers and non-carriers.\n\n* Healthy adult volunteers must be 18 years of age or older, and must agree to have blood or tissue samples studied, and potentially stored for future research.\n* Index cases enrolled in this protocol will have been referred with a known or suspected pathology that may be associated with cardiovascular dysfunction or risk with a suspected atypical presentation, heritable disorder, or genetic predisposition. The investigator with expertise in the presentation of the subject, along with consulting specialists, will review the medical history and may review any medical records that are available of prospective subjects and offer admission based upon the potential to help the individual, to learn from the subject, or to initiate clinical or basic research suggested by the subject s workup.\n\nEXCLUSION CRITERIA:\n\n* Persons of less than 1 year of age or greater than 100 years of age\n* Healthy volunteers unable to give informed consent or who decline to have blood and\u002For tissue studies, or who do not consent to have samples stored for future research may be excluded from this study.\n* Pregnant women\n* Persons who are not fluent in the English language will be excluded from Patient Reported Outcome Questionnaires. Such persons would be unable to properly complete questionnaires that are only valid in the English language.",true,"ALL","1 Year","100 Years",{"count":22,"type":23},5000,"ESTIMATED","OBSERVATIONAL","Background:\n\n\\- Researchers are interested in studying individuals who have known or suspected metabolic, inflammatory or genetic diseases that may put them at a high risk for heart diseases or diseases of their blood vessels. Depending on the condition being studied, both affected and nonaffected individuals may be asked to provide blood and other samples and may undergo tests to evaluate the heart, blood vessels and lung function. The testing is tailored to the individual and\u002For condition being studied. Nonaffected individuals may include relatives of affected individuals and healthy nonrelated volunteers.\n\nObjectives:\n\n\\- To study individuals who have or are at risk for cardiovascular diseases, and in some cases their unaffected relatives and healthy volunteers.\n\nEligibility:\n\n\\- Individuals between 1 and 100 years of age. Participants may be healthy volunteers, individuals with cardiovascular diseases, or unaffected relatives of individuals with cardiovascular diseases.\n\nDesign:\n\n* Participants will have some or all of the following tests, as directed by the study researchers:\n* Photography of the face and full body\n* Body measurements\n* Radiography, including chest or limb x-rays\n* Metabolic stress testing to study heart and muscle function\n* Echocardiography to study heart function\n* Magnetic resonance imaging (MRI) studies, including cardiovascular MRI, angiography, and contrast MRI, to study heart function and performance\n* Computed tomography (CT) angiogram to obtain images of the heart and lungs\n* Positron emission tomography (PET) imaging to study possible fat infiltration of the heart\n* Six-minute walk test to study heart, lung, and muscle function and performance\n* Vascular ultrasound to study blood vessel walls\n* Blood, tissue, and other specimens will be collected for research and testing, and will be taken either as part of the clinical study or during surgical procedures.\n* Follow-up studies may be performed under separate research protocols.",[27,28,29,30,31,32],"Metabolic Disease","Obesity","Li-Fraumeni Syndrome","Cardiomyopathy","Atherosclerosis","Inflammatory Disease",[34,35,36,37,38,39,40],"Cardiac Disease","iPS Cells","Cardiac Risk Factors","Cardiac Disease Discovery","Natural History","Heart Disease","Heart Disease Risk","RECRUITING","2026-06-30",{"date":44,"type":45},"2026-07-01","ACTUAL",{"date":47,"type":45},"2010-07-21",{"name":49,"class":50},"National Heart, Lung, and Blood Institute (NHLBI)","NIH",3,{"id":53,"slug":54,"hasResults":12,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":12,"sex":18,"minAge":59,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":62,"conditions":63,"keywords":64,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":76},"100634603","effectiveness-and-treatment-patterns-of-mavacamten-in-patients-with-obstructive-hypertrophic-cardiomyopathy-in-japan-manage-hcm-100634603","NCT07541833","Effectiveness and Treatment Patterns of Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan (MANAGE-HCM)","A Study Evaluating Effectiveness and Treatment Patterns of Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy Treated With Cibenzoline in Japan (MANAGE-HCM)","Inclusion Criteria:\n\n• Signed informed consent form (ICF): Participants, or their legally acceptable representative, must have signed and dated an Institutional Review Board (IRB)\u002FIndependent Ethics Committee (IEC)-approved ICF in accordance with regulatory, local, and institutional guidelines. This must be obtained before the performance of any protocol-related procedures.\n\n* Diagnosed with obstructive hypertrophic cardiomyopathy (HOCM) consistent with Japanese Circulation Society guidelines (2025), i.e., satisfy all criteria below:\n\n  * Has unexplained left ventricular (LV) hypertrophy with nondilated ventricular chambers in the absence of other cardiac (e.g., hypertension, aortic stenosis) or systemic disease and with maximal LV wall thickness ≥ 15 mm (or ≥ 13 mm with positive family history of HCM).\n  * Has Left Ventricular Outflow Tract (LVOT) peak gradient ≥ 30 mmHg (resting, Valsalva maneuver, or post-exercise).\n* Has documented Left Ventricular Ejection Fraction (LVEF) ≥ 55% at baseline.\n* Participants who meet any of the following criteria:\n\n  * Participants who have previously received mavacamten continuously for ≥ 16 weeks\n  * Participants who are currently receiving mavacamten\n  * Participants who are scheduled to receive mavacamten\n* Treated with a stable dose of cibenzoline for at least 3 months prior to initiating mavacamten treatment. Tapered cibenzoline within 3 months prior to initiating mavacamten treatment is allowed if stable dose of cibenzoline was used for at least 3 months prior to tapering.\n* At least 18 years of age at the time of signing the informed consent.\n\nExclusion Criteria:\n\n* Hypersensitivity to the active substance or to any of the excipients.\n* During pregnancy and in women of childbearing potential.\n* Treated with strong CYP3A4 inhibitors (itraconazole, clarithromycin, voriconazole, posaconazole, ritonavir, cobicistat, ceritinib, ensitrelvir fumaric acid, lonafarnib, josamycin, or mifepristone\u002Fmisoprostol).\n* Severe hepatic impairment (Child-Pugh C).\n* Severe atrioventricular block or severe sinoatrial block.\n* Congestive heart failure.\n* Requiring dialysis.\n* Angle-closure glaucoma.\n* Tendency to urinary retention.\n* Treated with vardenafil hydrochloride hydrate, moxifloxacin hydrochloride, lascufloxacin hydrochloride (injection), toremifene citrate, fingolimod hydrochloride, siponimod fumarate, or eliglustat tartrate.\n* Mavacamten treatment within 8 weeks prior to baseline. Mavacamten treatment initiation was judged based on post-exercise LVOT peak gradient.","18 Years",{"count":61,"type":23},36,"The purpose of this study is to assess the real-world effectiveness and safety of mavacamten in adults diagnosed with symptomatic obstructive hypertrophic cardiomyopathy (HOCM) receiving cibenzoline in Japan",[30],[65],"hypertrophic cardiomyopathy (HOCM)","2026-06-25",{"date":68,"type":45},"2026-06-26",{"date":70,"type":45},"2026-02-05",{"date":72,"type":23},"2026-12-31",{"name":74,"class":75},"Bristol-Myers Squibb","INDUSTRY",1,{"id":78,"slug":79,"hasResults":12,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":84,"targetDuration":86,"studyType":24,"phases":4,"briefSummary":87,"conditions":88,"keywords":92,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":108},"100644920","modeling-mortality-in-duchenne-muscular-dystrophy-cardiomyopathy-identification-of-surrogate-outcome-measures-for-dmd-drug-trials-100644920","NCT07674758","Modeling Mortality in Duchenne Muscular Dystrophy Cardiomyopathy: Identification of Surrogate Outcome Measures for DMD Drug Trials","Evaluating Cardiac Function in Patients With Duchenne Muscular Dystrophy","Inclusion Criteria:\n\n* Clinical phenotype of Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), or muscular dystrophy carrier (MDC) confirmed with muscle biopsy or genotype\n\nExclusion Criteria:\n\n* Additional genetic or congenital abnormality that may affect cardiovascular function or progression\n* Current investigational therapy that may affect cardiovascular function (would preclude ongoing data collection but prior data would still be used)",{"count":85,"type":23},1000,"5 Years","Dystrophin associated heart dysfunction is a leading cause of death in patients with Duchenne and Becker Muscular dystrophy (DMD\u002FBMD) and Duchenne and Becker muscular dystrophy carriers (MDC); however, the evolution of heart dysfunction is not well-understood. The central objectives of this proposal are to elucidate this evolution of heart dysfunction and identify measures from cardiac MRI images that can predict death or significant heart disease in patients with DMD\u002FBMD\u002FMDC. This study will create a large clinical and cardiac MRI registry of dystrophin associated heart dysfunction, will utilize advanced image analysis techniques, including deep learning neural networks, to comprehensively evaluate every patient, and will create a risk toolkit accessible to clinicians around the world; this proposal has the potential to improve the quality of life in patients with dystrophin associated heart dysfunction by allowing for earlier and more intensive therapy in patients with severe disease and by identifying surrogate outcome measures for use in therapeutic trials.",[89,30,90,91],"Duchenne Muscular Dystrophy (DMD)","Becker Muscular Dystrophy","Carrier of Duchenne Muscular Dystrophy",[93,94,95,96,97,98],"Duchenne Muscular Dystrophy","cardiomyopathy","machine learning","cardiac MRI","Biomarker","Outcome measures","2026-06-24",{"date":42,"type":45},{"date":102,"type":45},"2025-01-06",{"date":104,"type":23},"2029-02-01",{"name":106,"class":107},"Vanderbilt University Medical Center","OTHER",9,{"id":110,"slug":111,"hasResults":12,"nctId":112,"briefTitle":113,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":17,"sex":18,"minAge":59,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":118,"phases":119,"briefSummary":121,"conditions":122,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":76},"100629820","phase-1-a-bioequivalence-study-of-two-formulations-of-hrs-1893-tablets-in-healthy-participants-100629820","NCT07479641","A Bioequivalence Study of Two Formulations of HRS-1893 Tablets in Healthy Participants","Inclusion Criteria:\n\n1. Subjects aged 18 to 55 years (inclusive), regardless of gender;\n2. Body mass index (BMI) between 19 and 28 kg\u002Fm² (inclusive), with body weight ≥ 50.0 kg and \\\u003C 90.0 kg for men, and ≥ 45.0 kg and \\\u003C 90.0 kg for women;\n3. No abnormalities of clinical significance are found upon comprehensive physical examination and laboratory tests, or only minor abnormalities that are deemed by the investigator not to affect the subject's eligibility for enrollment;\n4. No clinically significant abnormalities on the 12-lead ECG;\n5. The subject must understand the study procedures and methods, voluntarily agree to participate, and provide written informed consent.\n\nExclusion Criteria:\n\n1. Subjects with suspected hypersensitivity to the investigational drug or any excipient;\n2. The subject has a history of syncope;\n3. Exclusion due to blood pressure: Systolic Blood Pressure (SBP) \\>140 mmHg or \\\u003C90 mmHg; OR Diastolic Blood Pressure (DBP) \\>90 mmHg or \\\u003C60 mmHg, as determined by the investigator to be clinically significant;\n4. History of gastric or intestinal surgery that, in the investigator's judgment, may affect drug absorption;\n5. A positive result in any one of the following infectious disease screening tests during the screening period: hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV-Ab), treponema pallidum antibody (syphilis), or human immunodeficiency virus antibody\u002Fantigen (HIV-Ab\u002FAg);\n6. Subjects who meet any of the following criteria will be excluded: a. Smoking: Average daily cigarette consumption of more than 5 cigarettes within the 4 weeks prior to screening; b. Alcohol: Average daily alcohol intake exceeding 15 g within one week prior to screening (15 g of alcohol is equivalent to 450 mL of beer, 150 mL of wine, or 50 mL of low-alcohol spirits); c. Non-compliance: Inability or unwillingness to abstain from smoking, alcohol, and caffeine-containing foods or beverages during the screening period and the entire study duration; d. Diet: Have special dietary requirements, cannot comply with the standardized diet provided in the study, or have a history of substance abuse;\n7. History of substance abuse;\n8. Use of any prescription drugs, over-the-counter medications, or Chinese herbal medicines within 1 month prior to dosing, or the use of any drug within 5 half-lives prior to screening (whichever is longer). Additionally, subjects who plan to take any non-study medications during the trial period will be excluded;\n9. Any other circumstances that, in the investigator's judgment, make the subject unsuitable for participation in the trial. This includes physiological or psychological conditions that may increase the trial risk, affect the subject's protocol compliance, or impact the subject's ability to complete the study.","55 Years",{"count":117,"type":23},58,"INTERVENTIONAL",[120],"PHASE1","This study will investigate the bioequivalence between two formulations of HRS-1893 tablets. Safety and tolerability will also be assessed.",[30],{"date":124,"type":45},"2026-06-29",{"date":126,"type":45},"2026-04-14",{"date":128,"type":23},"2026-07",{"name":130,"class":75},"Shandong Suncadia Medicine Co., Ltd.",{"id":132,"slug":133,"hasResults":12,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":12,"sex":18,"minAge":138,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":141,"conditions":142,"keywords":144,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":156},"100582605","clinical-course-of-disease-in-participants-with-fa-cm-100582605","NCT06865482","Clinical Course Of Disease In Participants With FA-CM","Characteristics And Clinical Course Of Disease In Participants With Cardiomyopathy Associated With Friedreich Ataxia (CLARITY-FA)","Inclusion Criteria:\n\n* Male or female, ages ≥6 years at the time of signing the informed consent (and assent, if applicable).\n* Diagnosis of FA, based on clinical phenotype and genotype (GAA expansion on both alleles or compound heterozygous), with onset of FA occurring at ≤25 years of age\n* Confirmed left ventricular hypertrophy (LVH)\n* Left ventricular ejection fraction ≥40%\n\nExclusion Criteria:\n\n* Presence of other form(s) of CM contributing to heart failure (HF), clinically significant cardiac anatomic abnormality or congenital cardiac malformation, clinically significant coronary artery, uncorrected, hemodynamically significant primary structural valvular disease not due to CM\n* Currently receiving intermittent or continuous intravenous (IV) inotrope infusion, presence of a ventricular assist device, or history of prior heart transplantation\n* Contraindication to cMRI, participants \\\u003C12 years of age who cannot complete the cMRI without sedation will instead undergo ECHOs and are exempt from this criterion.\n* Prior organ transplantation\n* Initiation of cardiac resynchronization therapy (CRT) within 6 months prior to screening.\n* History of prior gene transfer or cell therapy.\n* Poorly controlled diabetes (hemoglobin A1c ≥8%)\n* Active hematologic or solid organ malignancy","6 Years",{"count":140,"type":23},65,"Characteristics and clinical course of disease In participants with cardiomyopathy associated with Friedreich Ataxia (CLARITY-FA)",[143,30],"Friedreich Ataxia",[143,145,30,146,34],"FA-CM","FA","2026-06-04",{"date":149,"type":45},"2026-06-08",{"date":151,"type":45},"2025-09-30",{"date":153,"type":23},"2027-09",{"name":155,"class":75},"Lexeo Therapeutics",19,{"id":158,"slug":159,"hasResults":12,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":12,"sex":18,"minAge":59,"maxAge":4,"enrollmentInfo":165,"targetDuration":167,"studyType":24,"phases":4,"briefSummary":168,"conditions":169,"keywords":174,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":76},"100638834","multimodal-magnetic-resonance-imaging-in-cardiovascular-disease-100638834","NCT07617844","Multimodal mAgnetic Resonance imaGIng in Cardiovascular Disease","Multimodal-MRI in Cardiovascular Diseases","MAGIC","Inclusion Criteria:\n\n* Aged 18 years and older, with no gender restrictions.\n\nClinically suspected or confirmed cardiovascular disease (including but not limited to ischemic heart disease, non-ischemic cardiomyopathy, myocarditis, valvular disease, etc.), requiring a cardiac magnetic resonance (CMR) examination to determine the etiology or evaluate myocardial tissue characteristics.\n\nNo contraindications to magnetic resonance examination, and able to cooperate with breath-holding instructions.\n\nVoluntarily participate in this study and sign a written informed consent form.\n\nExclusion Criteria:\n\n* Absolute contraindications: Implantation of non-MRI compatible metallic foreign bodies (e.g., old pacemakers, implantable cardioverter-defibrillators \\[ICD\\], aneurysm clips, etc.).\n\nRelative contraindications: Severe claustrophobia, unable to complete the examination despite communication.\n\nSevere renal insufficiency.\n\nSpecial populations: Pregnant or lactating women.\n\nPresence of severe arrhythmias (e.g., persistent atrial fibrillation) leading to severely impaired magnetic resonance signal acquisition, rendering the image quality inadequate for diagnosis.\n\nPoor expected compliance: Unable to complete follow-up, or deemed unsuitable for enrollment by the investigator for other reasons.",{"count":166,"type":23},2000,"3 Years","This single-center, prospective, observational cohort study aims to evaluate the clinical application value of multi-modal cardiovascular magnetic resonance (CMR) imaging in patients with cardiovascular diseases (CVD).\n\nWhile traditional imaging methods have limitations in fully evaluating myocardial tissue characteristics, multi-modal CMR offers a comprehensive, non-invasive \"one-stop\" assessment. It can simultaneously evaluate heart structure, function, tissue features (such as fibrosis and edema), and hemodynamics.\n\nThe study plans to enroll patients with suspected or confirmed CVD. Participants will undergo a comprehensive multi-modal CMR scan (including Cine, T1\u002FT2 mapping, Late Gadolinium Enhancement, and 4D flow sequences) as part of their evaluation. By tracking clinical outcomes, the study seeks to establish a standardized imaging assessment system to improve the early detection, accurate diagnosis, risk stratification, and prognostic prediction for various types of cardiovascular diseases.",[170,171,30,172,173],"Cardiovascular Diseases","Ischemic Heart Disease (IHD)","Myocarditis","Heart Valve Diseases",[175,176,177],"Cardiac Magnetic Resonance","Magnetic Resonance Imaging","Multimodal Imaging","2026-05-26",{"date":180,"type":45},"2026-06-01",{"date":182,"type":45},"2026-01-01",{"date":184,"type":23},"2028-12-31",{"name":186,"class":107},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":188,"slug":189,"hasResults":12,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":193,"eligibilityCriteria":194,"healthyVolunteers":17,"sex":18,"minAge":195,"maxAge":196,"enrollmentInfo":197,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":199,"conditions":200,"keywords":204,"overallStatus":212,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":76},"100638540","petct-imaging-in-carriers-of-ttr-mutations-100638540","NCT07591038","PET\u002FCT Imaging in Carriers of TTR Mutations","Iodine-124 Evuzamitide PET\u002FCT Imaging in Carriers of TTR Mutations","EPIC-TTR","A. Pathogenic TTR Allele Carriers without HF\n\nInclusion:\n\n* men and women ages 30-80 who are pathogenic allele TTR carriers without history of HF (this will be assessed by study personnel and defined as : 1) No history of hospitalization within the previous 12 months for management of HF; 2) Without an elevated B-type natriuretic peptide level ≥100 pg\u002FmL or NT-proBNP ≥360 pg\u002FmL within the previous 12 months; or 3) a clinical diagnosis of HF from a treating clinician)\n* have already completed the protocol for NCT05489549 at UT Southwestern only\n\nExclusion:\n\n* a self-reported history or clinical history of HF\n* other known causes of cardiomyopathy\n* history of light-chain cardiac amyloidosis\n* prior type 1 myocardial infarction\n* cardiac transplantation\n* liver transplantation\n* body weight or habitus that exceeds the site-specific PET\u002FCT parameters\n* estimated glomerular filtration rate ≤30 mL\u002Fmin\u002F1.73 m2\n* inability to safely undergo PET\u002FCT\n* participating in a clinical trial for ATTR treatments or taking a fibril deleting agent\n* pregnancy or breastfeeding\n* patients taking heparin or heparin derivatives for anticoagulation\n* allergy to potassium iodide\n* known uncorrected thyroid disorder\n\nB. Subjects with symptomatic hATTR-CA (may be supplemented with other ATTR-CA genotypes including wild-type in the occasion of slow enrollment):\n\nInclusion:\n\n* men and women ages 30-80 who have symptomatic V122I hATTR-CA as determined by a history of HF (this will be assessed by study personnel and defined as : 1) history of hospitalization within the previous 12 months for management of HF; 2) an elevated B-type natriuretic peptide level ≥100 pg\u002FmL or NT-proBNP ≥360 pg\u002FmL within the previous 12 months; or 3) a clinical diagnosis of HF from a treating clinician)\n* hATTR-CA previously diagnosed histologically by amyloid staining and tissue typing with immunohistochemistry or mass spectrometry or by bone scintigraphy in without abnormal M-protein\n* TTR gene sequencing confirming the TTR variant\n* have already completed the protocol for NCT05489549 at UT Southwestern only\n\nExclusion:\n\n* other known causes of cardiomyopathy\n* history of light-chain cardiac amyloidosis\n* cardiac transplantation\n* liver transplantation\n* history of type I myocardial infarction\n* body weight or habitus that exceeds the site-specific PET\u002FCT parameters\n* estimated glomerular filtration rate ≤30 mL\u002Fmin\u002F1.73 m2\n* inability to safely undergo PET\u002FCT\n* participating in a clinical trial for ATTR treatments or taking a fibril deleting agent\n* patients taking heparin or heparin derivatives for anticoagulation\n* pregnancy or breastfeeding\n* allergy to potassium iodide\n* known uncorrected thyroid disorder\n\nC. Non-carrier race-matched controls:\n\nInclusion:\n\n* men and women ages 30-80 who are non-carriers without history of HF (this will be assessed by study personnel and defined as: 1) No history of hospitalization within the previous 12 months for management of HF; 2) Without an elevated B-type natriuretic peptide level ≥100 pg\u002FmL or NT-proBNP ≥360 pg\u002FmL within the previous 12 months; or 3) No clinical diagnosis of HF from a treating clinician\n* have previously enrolled in the Dallas Heart Study\n\nExclusion:\n\n* a self-reported history or clinical history of HF\n* other known causes of cardiomyopathy\n* history of light-chain cardiac amyloidosis\n* prior type 1 myocardial infarction\n* cardiac transplantation\n* liver transplantation\n* body weight or habitus that exceeds the site-specific PET\u002FCT parameters\n* estimated glomerular filtration rate ≤30 mL\u002Fmin\u002F1.73 m2\n* inability to safely undergo PET\u002FCT\n* participating in a clinical trial for ATTR treatments or taking a fibril deleting agent\n* patients taking heparin or heparin derivatives for anticoagulation\n* pregnancy or breastfeeding\n* allergy to potassium iodide\n* known uncorrected thyroid disorder","30 Years","80 Years",{"count":198,"type":23},80,"The purpose of this study is to determine if TTR gene carriers have early signs of a type of heart disease called amyloidosis using a new radiotracer dye (iodine-124 evuzamitide, I-124E).\n\nParticipants will undergo a screening that includes a medical history review and completion of quality-of-life surveys. Once screening is complete, participants will undergo an imaging test called a positron emission tomography (PET) scan combined with computed tomography (PET\u002FCT) to make images of the body. The new radiotracer dye (I-124E, a radioactive contrast) will be used during the PET\u002FCT to make amyloidosis visible in the heart and body.",[201,202,30,203],"ATTR","ATTR Gene Mutation","Transthyretin Mediated Amyloidosis (ATTR)",[205,206,207,208,209,210,201,211],"transthyretin","amyloidosis","carriers of abnormal gene","TTR","PET\u002FCT","evuzamitide","TTR gene","NOT_YET_RECRUITING","2026-05-15",{"date":215,"type":45},"2026-05-19",{"date":217,"type":23},"2026-08-01",{"date":219,"type":23},"2030-06-30",{"name":221,"class":107},"University of Texas Southwestern Medical Center",{"id":223,"slug":224,"hasResults":12,"nctId":225,"briefTitle":226,"officialTitle":227,"acronym":4,"eligibilityCriteria":228,"healthyVolunteers":12,"sex":18,"minAge":59,"maxAge":4,"enrollmentInfo":229,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":231,"conditions":232,"keywords":235,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":76},"100641056","aic-genotyping-study-100641056","NCT07574697","AIC Genotyping Study","Genetic Susceptibility to AF-Induced Cardiomyopathy","INCLUSION:\n\nAIC (Cases):\n\n* Age ≥18\n* Persistent AF before index catheter ablation or cardioversion\n* LVEF ≤40% during rate-controlled (resting HR \\\u003C100bpm, mean HR on 24-hour Holter \\\u003C100bpm) AF prior to index catheter ablation or cardioversion\n* LVEF normalisation (LVEF ≥55%) in SR, post-catheter ablation or cardioversion (≥3 months post-catheter ablation or cardioversion), no AF (\\>30 seconds of continuous AF) detected outside blanking period (8 weeks post-catheter ablation), and with no new introduction of any new or increased dose of heart failure guideline-directed medical therapy (GDMT) (renin-angiotensin-aldosterone system inhibitors (RAASi), Sodium Glucose Co-transporter 2 (SLGT2) inhibitors, increased dose of beta-blocker (BB), mineralocorticoid receptor antagonist (MRA))\n\nAF-pEF (Negative controls):\n\n* Age ≥18\n* Persistent AF before index catheter ablation or cardioversion\n* LVEF ≥55% during rate-controlled (resting HR \\\u003C100bpm) AF. AIC-genotyping study, v1.7, 27.01.26 Page 13 of 28\n\nAF\u002FHF non-responders (Positive controls)\n\n* Age ≥18\n* Persistent AF before index catheter ablation or cardioversion\n* LVEF ≤40% during rate-controlled (resting HR \\\u003C100bpm) AF before index catheter ablation or cardioversion.\n* Persistent LVSD (LVEF ≤40%) in SR, post-catheter ablation or cardioversion (≥3 months post-catheter ablation or cardioversion), no AF (\\>30 seconds of continuous AF) detected outside blanking period (8 weeks post-catheter ablation) and with no change in heart failure GDMT (RAASi, SGLT2 inhibitors, increased dose of BB, MRA).\n\nEXCLUSION:\n\nAIC (Cases).\n\n* No alternative cause for LVSD (ischemic cardiomyopathy\u002Fnon-ischaemic cardiomyopathy before AF diagnosis, primary valve disease, inherited cardiomyopathy\n* Any pregnancy during AF or in the 12 months preceding LVSD onset.\n* Alcohol intake \\>21 units\u002Fweek\n* Any history of cardiotoxic chemotherapy\n\nAF-pEF (Negative controls)\n\n* No known cause for LVSD (ischemic cardiomyopathy\u002Fnon-ischaemic cardiomyopathy before AF diagnosis, primary valve disease, inherited cardiomyopathy).\n* Any pregnancy during AF or in the 12 months preceding LVSD onset.\n* Alcohol intake \\>21 units\u002Fweek.\n* Any history of cardiotoxic chemotherapy.\n\nAF\u002FHF non-responders (Positive controls)\n\n* No alternative cause for LVSD (ischemic cardiomyopathy\u002Fnon-ischaemic cardiomyopathy before AF diagnosis, primary valve disease, inherited cardiomyopathy).\n* Any pregnancy during AF or in the 12 months preceding LVSD onset.\n* Alcohol intake \\>21 units\u002Fweek.\n* Any history of cardiotoxic chemotherapy.",{"count":230,"type":23},299,"To quantify genetic variants in a focused DCM gene panel among AF-induced cardiomyopathy (AIC) and positive\u002Fnegative controls",[30,233,234],"Atrial Fibrillation (AF)","Genetic",[236,237,238],"prospective","case-controlled","genetics","2026-05-05",{"date":241,"type":45},"2026-05-08",{"date":243,"type":45},"2026-03-25",{"date":245,"type":23},"2027-05-31",{"name":247,"class":107},"Barts & The London NHS Trust",{"id":249,"slug":250,"hasResults":12,"nctId":251,"briefTitle":252,"officialTitle":253,"acronym":4,"eligibilityCriteria":254,"healthyVolunteers":12,"sex":18,"minAge":59,"maxAge":4,"enrollmentInfo":255,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":257,"conditions":258,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":76},"100616676","a-study-of-deep-learning-for-echo-analysis-tracking-and-evaluation-100616676","NCT07308704","A Study Of Deep Learning For Echo Analysis, Tracking, And Evaluation","DELINEATE-Deploy: Deep Learning for Echo Analysis, Tracking, and Evaluation - Prospective Deployment Platform IRB","Inclusion criteria:\n\n* Genetic cardiomyopathy arm: Clinicians who order, perform, and interpret echocardiograms and act on echocardiogram results, including both physicians and allied health staff taking care of patients aged ≥18 years who are undergoing a comprehensive TTE at a participating Mayo Clinic site with AI-Echo analysis indicating high risk for a genetic cardiomyopathy. A high-risk score will be defined by a specific threshold determined in model development to maximize sensitivity while maintaining an adequate positive predictive value to support clinical deployment\n* Ischemic cardiomyopathy arm: Clinicians who order, perform, and interpret echocardiograms and act on echocardiogram results, including both physicians and allied health staff taking care of patients aged ≥18 years who are undergoing a comprehensive TTE with AI-Echo analysis indicating high risk for ischemic cardiomyopathy. A high-risk score will be defined by a specific threshold determined in model development to maximize sensitivity while maintaining an adequate positive predictive value to support clinical deployment.\n* Cardiac amyloidosis arm: Clinicians who order, perform, and interpret echocardiograms and act on echocardiogram results, including both physicians and allied health staff taking care of patients aged ≥18 years who are undergoing a comprehensive TTE with AI-Echo analysis indicating high risk for cardiac amyloidosis. A high-risk score will be defined by a specific threshold determined in model development to maximize sensitivity while maintaining an adequate positive predictive value to support clinical deployment.\n* Hypertrophic cardiomyopathy (HCM) arm: Clinicians who order, perform, and interpret echocardiograms and act on echocardiogram results, including both physicians and allied health staff caring for patients aged ≥18 years who are undergoing a comprehensive TTE at a participating Mayo Clinic site, with AI-Echo analysis indicating high risk for HCM. A high-risk score will be defined by a specific threshold determined during model development to maximize sensitivity while maintaining adequate positive predictive value for clinical deployment.\n\nExclusion criteria:\n\n* Genetic cardiomyopathy arm: Studies performed within the past 2 years at a Mayo site or in those patients with known or suspected diagnosis of genetic cardiomyopathy under evaluation, on hospice care, or who have an expected non-cardiac life expectancy \\\u003C1 year, and patients who have opted out of institutional and state research authorizations.\n* Ischemic cardiomyopathy arm: Studies performed within the past 2 years at a Mayo site or in those patients with known CAD; prior myocardial infarction; revascularization with PCI or CABG; ischemic testing within the past 12 months; hospice care or expected non-cardiac life expectancy \\\u003C1 year, and patients who have opted out of institutional and state research authorizations.\n* Cardiac amyloidosis arm: Studies performed within the past 2 years at a Mayo site or in those patients with prior amyloid-specific testing (e.g., technetium pyrophosphate scan, cardiac MRI with late gadolinium enhancement suggestive of amyloid) or biopsy-proven systemic amyloidosis, on hospice care, or have expected non-cardiac life expectancy \\\u003C1 year, and patients who have opted out of institutional and state research authorizations.\n* Hypertrophic cardiomyopathy (HCM) arm: Studies performed within the past 2 years at a Mayo site or patients with a known diagnosis of HCM documented in the medical record prior to the index TTE, prior septal reduction therapy (surgical myectomy or alcohol septal ablation), or patients on hospice care or with an expected non-cardiac life expectancy \\\u003C1 year, and patients who have opted out of institutional and state research authorizations.",{"count":256,"type":23},10040000,"The purpose of this study is to deploy and evaluate informational AI-Echo algorithms that assist echo clinicians in interpreting core echocardiographic parameters (e.g., LV\u002FRV size and function, valvular disease severity) and stratifying disease progression risk. The primary outcome is clinician usability, interpretive consistency, and workflow integration. Second, we will conduct a pragmatic, stepped-wedge clinical trial with multiple arms evaluating diagnostic AI-Echo algorithms designed to identify specific cardiovascular diseases- such as genetic cardiomyopathy, ischemic heart disease, and cardiac amyloidosis-and assess whether AI deployment increases diagnostic testing and shortens time to diagnosis. Trials will be conducted using EHR-based notification systems with cluster-level randomization.",[30,259,260],"Ischemic Heart Disease","Cardiac Amyloidosis","2026-04-15",{"date":263,"type":45},"2026-04-16",{"date":265,"type":45},"2026-02-26",{"date":267,"type":23},"2028-02",{"name":269,"class":107},"Mayo Clinic",{"id":271,"slug":272,"hasResults":12,"nctId":273,"briefTitle":274,"officialTitle":275,"acronym":4,"eligibilityCriteria":276,"healthyVolunteers":12,"sex":277,"minAge":278,"maxAge":279,"enrollmentInfo":280,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":281,"conditions":282,"keywords":283,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":299,"locationsCount":76},"100632557","dmd-gene-variants-and-cardiac-dysfunction-in-young-males-with-dystrophinopathies-100632557","NCT07515235","DMD Gene Variants and Cardiac Dysfunction in Young Males With Dystrophinopathies","Correlation of Pathogenic Variants in the DMD Gene With Cardiac Dysfunction in Male Children, Adolescents, and Young Adults With Dystrophinopathies: A Pilot Study","Inclusion Criteria:\n\n* Male sex\n* Age between 2 and 24 years at the time of enrollment\n* Genetically confirmed dystrophinopathy with a pathogenic or likely pathogenic variant in the DMD gene\n* Genetic confirmation based on at least one validated method, including MLPA, NGS, Sanger sequencing, array-CGH, or qPCR\n* Written informed consent from parents or legal guardians and, where applicable, consent from the participant\n\nExclusion Criteria:\n\n* Absence of a genetically confirmed diagnosis of dystrophinopathy, including:\n* diagnosis based solely on muscle biopsy without molecular confirmation of a pathogenic or likely pathogenic DMD gene variant\n* absence of a confirmed pathogenic variant in the DMD gene, even if maternal carrier status has been identified, unless repeat genetic testing confirms a pathogenic variant in the participant\n* Presence of congenital heart disease or other genetic disorders causing primary cardiomyopathy\n* Presence of other neuromuscular disorders\n* Female carriers, including both manifesting and asymptomatic carriers\n* Comorbidities that may independently affect cardiac function, such as severe arterial hypertension, diabetes mellitus, or chronic kidney disease","MALE","2 Years","24 Years",{"count":140,"type":23},"The goal of this observational study is to investigate whether the type, location, and extent of pathogenic variants in the DMD gene are associated with cardiac dysfunction in male children, adolescents, and young adults with dystrophinopathies. The study also evaluates whether cardiac biomarkers and electrocardiographic findings can facilitate the early identification of cardiac involvement. Participants will undergo electrocardiography, blood sampling for cardiac biomarker assessment, and transthoracic echocardiography, with cardiac dysfunction evaluated using ejection fraction (EF) and global longitudinal strain (GLS).",[89,90,30],[284,285,286,287,288,289,290,291,292],"DMD gene","Non-HDL Cholesterol","NT-proBNP","Dystrophinopathy","Duchenne muscular dystrophy","Becker muscular dystrophy","Cardiac dysfunction","Global longitudinal strain","hs-TnT","2026-03-31",{"date":295,"type":45},"2026-04-07",{"date":297,"type":45},"2026-01-26",{"date":267,"type":23},{"name":300,"class":107},"Aristotle University Of Thessaloniki",{"id":302,"slug":303,"hasResults":12,"nctId":304,"briefTitle":305,"officialTitle":306,"acronym":307,"eligibilityCriteria":308,"healthyVolunteers":12,"sex":18,"minAge":59,"maxAge":4,"enrollmentInfo":309,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":310,"conditions":311,"keywords":313,"overallStatus":212,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":321,"locationsCount":4},"100625853","french-registry-late-gadolinium-enhancement-in-hypertrophic-cardiomyopathy-100625853","NCT07428031","French Registry: Late Gadolinium Enhancement in Hypertrophic Cardiomyopathy","Retrospective French Registry of Cardiovascular Magnetic Resonance Late Gadolinium Enhancement in Patients With Hypertrophic Cardiomyopathy","HCM-LGE","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Ability to provide informed consent\n3. HCM diagnosis referred for CMR assessment.\n\nExclusion Criteria:\n\n1. Patients unable to provide informed consent,\n2. Patients with a history of ischemic cardiomyopathy or myocarditis.",{"count":22,"type":23},"This study aims to create a registry of patients with hypertrophic cardiomyopathy, a condition characterized by excessive thickening of the heart muscle. This disease can sometimes lead to serious complications. Currently, the prognosis of these patients is mainly determined by clinical and echocardiographic parameters. Detection of myocardial fibrosis using cardiac MRI enables better risk stratification for these patients.",[30,312],"Hypertrophic Cardiomyopathies",[175,30],"2026-02-16",{"date":316,"type":45},"2026-02-23",{"date":318,"type":23},"2026-03-01",{"date":320,"type":23},"2036-03-01",{"name":322,"class":107},"Assistance Publique - Hôpitaux de Paris",{"id":324,"slug":325,"hasResults":12,"nctId":326,"briefTitle":327,"officialTitle":328,"acronym":329,"eligibilityCriteria":330,"healthyVolunteers":12,"sex":18,"minAge":59,"maxAge":4,"enrollmentInfo":331,"targetDuration":4,"studyType":118,"phases":333,"briefSummary":335,"conditions":336,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":347,"startDateStruct":349,"completionDateStruct":351,"leadSponsor":353,"locationsCount":355},"100601901","a-study-assessing-arrhythmia-mapping-with-a-multi-electrode-mapping-catheter-100601901","NCT07116525","A Study Assessing Arrhythmia Mapping With a Multi-Electrode Mapping Catheter","Clinical Evaluation of Arrhythmia Mapping With a Paddle-shaped, High-density, Multi-electrode Mapping Catheter","FEATHER","Inclusion Criteria:\n\n* Diagnosed with and candidate for clinically indicated catheter mapping and ablation procedure for the management of ventricular tachycardia, premature ventricular complex, atrial tachycardia or atrial fibrillation (participant having undergone a previous ablation procedure may be included)\n* At least one episode of the targeted arrhythmia (ventricular tachycardia, premature ventricular complex, atrial tachycardia or atrial fibrillation) must have been documented by electrocardiogram (ECG), Holter, loop recorder, telemetry, implanted device, or transtelephonic monitoring within 12 months prior to enrollment\n* Age 18 years or older\n* Signed Patient Informed Consent Form (ICF)\n* Able and willing to comply with all pre-, post-, and follow-up testing and requirements\n\nExclusion Criteria:\n\n* Study arrhythmia secondary to reversible cause, or secondary to electrolyte imbalance, thyroid disease, or non cardiac cause\n* Patients requiring left atrial procedures: left atrial size greater than (\\>) 55 millimeter (mm)\n* Left ventricular ejection fraction(LVEF) less than or equal to (\\\u003C=) 25 percentage (%) for participants with ventricular arrhythmia\n* LVEF \\\u003C= 40% for participants with atrial arrhythmia\n* Documented intracardiac thrombus as detected on imaging within 24 hours prior to insertion of the investigational catheter\n* Contraindication to anticoagulation (that is, heparin, warfarin, dabigatran)\n* History of blood clotting or bleeding abnormalities (example hypercoagulable state)\n* Myocardial infarction within the past 2 months (60 days)\n* Documented thromboembolic event (including transient ischemic attack \\[TIA\\]) within the past 12 months (365 days)\n* Uncontrolled heart failure or New York heart association (NYHA) function class IV\n* Implanted with a pacemaker or intracardiac cardiac defibrillator or appendage closure device within the past 6 weeks (42 days)\n* Patients with known untreatable allergy to contrast media\n* Active illness or active systemic infection or sepsis\n* Diagnosed atrial or ventricular myxoma, interatrial baffle or patch, tumor or other abnormality that precludes catheter introduction or manipulation\n* Significant congenital anomaly or medical problem that in the opinion of the investigator would preclude enrollment in this study\n* Participants that have ever undergone a percutaneous or surgical valvular cardiac procedure (that is, ventriculotomy, atriotomy, and valve repair or replacement and presence of a prosthetic valve)\n* Participants that currently have Impella or equivalent devices on the procedure date or up to 7 days prior\n* Any cardiac surgery within the past 60 days (2 months) (includes percutaneous coronary intervention \\[PCI\\])\n* Atrial septal closure within the past 6 weeks (42 days)\n* Presence of a condition that precludes vascular access\n* Women who are pregnant (as evidenced by pregnancy test if pre-menopausal), lactating, or who are of childbearing age and plan on becoming pregnant during the course of the clinical investigation\n* Categorized as vulnerable population and requires special treatment with respect to safeguards of well-being\n* Concurrent enrollment in an investigational study evaluating another device or drug",{"count":332,"type":23},60,[334],"NA","The purpose of this study is to assess the safety and feasibility of the investigational catheter for mapping the atrial and ventricular regions of the heart.",[337,338,339,340,341,342,343,30,344,345],"Scar-related Atrial Tachycardia","Persistent Atrial Fibrillation","Paroxysmal Atrial Fibrillation","Ventricular Procedures","Ventricular Tachycardia","Ischemic Ventricular Tachycardia","Non-ischemic Ventricular Tachycardia","Idiopathic Ventricular Tachycardia","Premature Ventricular Contraction","2026-02-12",{"date":348,"type":45},"2026-02-13",{"date":350,"type":45},"2025-09-15",{"date":352,"type":23},"2026-09-30",{"name":354,"class":75},"Biosense Webster, Inc.",6,{"id":357,"slug":358,"hasResults":12,"nctId":359,"briefTitle":360,"officialTitle":361,"acronym":4,"eligibilityCriteria":362,"healthyVolunteers":12,"sex":18,"minAge":59,"maxAge":4,"enrollmentInfo":363,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":365,"conditions":366,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":370,"startDateStruct":372,"completionDateStruct":374,"leadSponsor":376,"locationsCount":377},"100478277","trpc6-characterization-to-predict-and-prevent-chemotherapy-related-cardiomyopathy-and-heart-failure-with-breast-cancer-100478277","NCT05507879","TRPC6 Characterization to Predict and Prevent Chemotherapy Related Cardiomyopathy and Heart Failure With Breast Cancer","Characterization of TRPC6 to Predict and Prevent Chemotherapy Related Cardiomyopathy and Heart Failure (Prospective Study)","Inclusion Criteria:\n\n* 18 years of age or older\n* Any breast cancer patient initiating doxorubicin\u002Fother anthracycline and patients receiving trastuzumab without doxorubicin\u002Fanthracycline in the neoadjuvant\u002Fadjuvant setting\n* An understanding of the protocol and its requirements, risks, and discomforts\n* The ability and willingness to sign an informed consent\n* Diagnosed with therapy related cardiotoxicity defined as; cardiomyopathy, symptomatic heart failure, asymptomatic reduced systolic function, acute coronary syndrome, myocardial infarction, critical limb ischemia, cardiac arrhythmias or myocarditis possibly related to prior cancer treatment OR completed chemotherapy with no cardiotoxicity at least two years post treatment OR patients with cancer who will be initiating systemic therapy with potentially cardiotoxic medications. This will include doxorubicin chemotherapy, or trastuzumab.\n* Healthy, non-pregnant, adult subjects who weigh at least 110 pounds\n\nExclusion Criteria:\n\n* Inability on the part of the patient to understand the informed consent or be compliant with the protocol\n* Anemia with hemoglobin less than 8\n* Patients not willing to undergo a blood draw\n* Patients with stage IV or distant metastatic breast cancer",{"count":364,"type":23},200,"This study examines TRPC6 in predicting and preventing chemotherapy related cardiac toxicity and heart failure in patients with breast cancer. Cardiac toxicity, changes in heart function is a well-recognized complication of certain cancer related therapies. Understanding these changes may allow early intervention against therapy-related cardiac toxicity and also identify novel therapeutic targets to protect patient long-term cardiac health. Studying samples of blood from patients with breast cancer in the laboratory may help doctors learn more about changes that occur in deoxyribonucleic acid (DNA), identify biomarkers related to cardiac toxicity, and prevent the development of therapy-induced cardiac toxicity in patients receiving chemotherapy.",[367,30,368],"Breast Carcinoma","Congestive Heart Failure","2026-02-06",{"date":371,"type":45},"2026-02-10",{"date":373,"type":45},"2022-09-26",{"date":375,"type":23},"2027-09-01",{"name":269,"class":107},2,{"id":379,"slug":380,"hasResults":12,"nctId":381,"briefTitle":382,"officialTitle":383,"acronym":4,"eligibilityCriteria":384,"healthyVolunteers":12,"sex":18,"minAge":59,"maxAge":196,"enrollmentInfo":385,"targetDuration":4,"studyType":118,"phases":387,"briefSummary":388,"conditions":389,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":393,"lastUpdatePostDateStruct":394,"startDateStruct":396,"completionDateStruct":398,"leadSponsor":400,"locationsCount":76},"100282907","phase-1-donor-bone-marrow-derived-mesenchymal-stem-cells-in-controlling-heart-failure-in-patients-with-cardiomyopathy-caused-by-anthracyclines-100282907","NCT02962661","Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines","Randomized 3-Arm Trial With Standard of Care Alone vs Either Intravenous Infusion or Transendocardial Injection of Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs) Plus Standard of Care in Patients With Anthracycline-Associated Cardiomyopathy","Inclusion Criteria:\n\n1. Patients with LVEF \\\u003C\u002F= 40% documented from treatment with anthracyclines for any malignancy at any dose at any time without evidence of other causes of cardiomyopathy.\n2. Age \\>\u002F= 18 and \\\u003C\u002F= 90 years of age. English and non-English speaking patients are eligible.\n3. Documented NYHA class I, II and III.\n4. For patients who have received trastuzumab: Persistent LV dysfunction must be present 90 days after discontinuation of trastuzumab.\n5. Able to perform 6 minute walk test.\n6. Been treated with appropriate maximal medical therapy for heart failure.\n7. Patient or legally authorized representative able to sign informed consent.\n\nExclusion Criteria:\n\n1. Evidence of Ischemic Heart Disease as determined by study cardiologist.\n2. Significant Valvular Disease. (AS with AVA \\\u003C1.5 and severe AR and MR)\n3. History of Familial Cardiomyopathy.\n4. Recent documented myocarditis within 2 months of enrollment.\n5. History of Infiltrative cardiomyopathy or restrictive cardiomyopathy.\n6. Presence of left ventricular thrombus as documented by echocardiography or left ventriculogram.\n7. Liver function tests \\> 3 x upper limit of normal.\n8. NYHA class IV heart failure.\n9. Inotropic dependence.\n10. Unstable or life-threatening arrhythmia.\n11. For patients not on anticoagulants, INR\\>1.5\n12. Mechanical or Bioprosthetic heart valve.\n13. Cardiogenic shock.\n14. Breastfeeding and\u002For pregnant women.\n15. Autoimmune disorders on current immunosuppressive therapy.\n16. Active infection not responding to appropriate therapy as determined by Study Chair.\n17. Trastuzumab treatment within the last 3 months.\n18. Automatic implantable cardioverter defibrillator (AICD) placement within the last 30 days.\n19. AICD firing within the last 30 days.",{"count":386,"type":23},72,[120],"This randomized pilot phase I trial studies the side effects of donor bone marrow derived mesenchymal stem cells in controlling heart failure in patients with cardiomyopathy caused by anthracyclines. Donor bone marrow derived mesenchymal stem cells may help to control symptoms of heart failure and improve heart function.",[30,390,391,392],"Heart Failure","Hematopoietic and Lymphoid Cell Neoplasm","Malignant Solid Neoplasm","2026-01-06",{"date":395,"type":45},"2026-01-07",{"date":397,"type":45},"2020-07-18",{"date":399,"type":23},"2026-07-30",{"name":401,"class":107},"M.D. Anderson Cancer Center",{"id":403,"slug":404,"hasResults":12,"nctId":405,"briefTitle":406,"officialTitle":406,"acronym":407,"eligibilityCriteria":408,"healthyVolunteers":12,"sex":18,"minAge":59,"maxAge":409,"enrollmentInfo":410,"targetDuration":4,"studyType":118,"phases":412,"briefSummary":413,"conditions":414,"keywords":416,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":420,"lastUpdatePostDateStruct":421,"startDateStruct":423,"completionDateStruct":425,"leadSponsor":426,"locationsCount":76},"100258274","molecular-imaging-of-primary-amyloid-cardiomyopathy-100258274","NCT02641145","Molecular Imaging of Primary Amyloid Cardiomyopathy","MICA","Inclusion criteria:\n\n* Age \\> 18 years\n* Diagnosis of light chain amyloidosis by standard criteria (immunofixation of serum and urine, IgG free light chain (FLC) assay, a biopsy of fat pad\u002F bone marrow, or organ biopsy, followed by typing of the light chain using immunohistochemistry or immunogold assay with confirmation by Mass spectroscopy as needed)\n\n  * For subjects traveling from out of town referred for systemic AL therapy based on clinical evaluation and laboratory testing, but, pending biopsy results, study enrollment and procedures may begin before official confirmation of biopsy results. If biopsy is negative for AL amyloidosis, subject will be considered a screen failure. There will be no more than 10 subjects who fall under this screen failure for the duration of the study.\n  * Subjects with localized amyloid deposition and non-systemic AL disease will be eligible for enrollment in group D.\n* Willing and able to provide consent\n* Additional inclusion criteria for the Remission AL-CMP: Hematological response defined as complete hematological remission or very good partial response-differential free light chain (dFLC)\\\u003C40 mg\u002FdL for \\> 1 year prior to enrollment\n* Additional inclusion criteria for the Active AL-CMP - exercise: Ability to perform supine bicycle exercise. Enrollment to this arm will stop after 36 subjects complete baseline and 6 months studies.\n* Additional inclusion criteria for the Active AL Pre-CMP - Normal left ventricular wall thickness (≤ 12 mm) and normal LVEF (≥55%) on echocardiography within 3 months or increased wall thickness with normal cardiac biomarker levels: not meeting above definition.\n* Additional inclusion criteria for Control Multiple Myeloma subjects: diagnosis of multiple myeloma without concomitant amyloidosis by standard criteria\n* Additional inclusion criteria for Control Heart Failure subjects: diagnosis of heart failure without amyloidosis by standard criteria\n* Additional inclusion criteria for the active AL-CMP: Abnormal TnT 5th generation levels (\\>9 ng\u002FL: Female, \\>14 ng\u002FL: Male) or abnormal age appropriate N terminal pro-brain natriuretic peptide, NT-proBNP (abnormal values: \\\u003C50 years: \\>450 pg\u002Fml; 50-75 years:\\>900 pg\u002Fml; \\>75 years: \\>1800 pg\u002Fml)\n\nExclusion Criteria:\n\n* Hemodynamic instability\n* Decompensated heart failure (unable to lie flat for 1 hour)\n* Concomitant non-ischemic non-amyloid heart disease (valvular heart disease or dilated cardiomyopathy)\n* Known obstructive epicardial coronary artery disease with stenosis \\> 50% in any single territory\n* Severe claustrophobia despite use of sedatives\n* Presence of MRI contraindications such as metallic implants (pacemaker or ICD) at the time of study enrollment except for Control Heart Failure subjects. Control HF subjects with no devices, or, with strictly MR compatible devices will be eligible to undergo MRI.\n* Significant renal dysfunction with estimated glomerular filtration rate \\\u003C 30 ml\u002Fmin\u002Fm2 within 14 days of each cardiac MRI study. Subjects who develop renal dysfunction over the course of the study, meeting criteria listed above, will be excluded from the cardiac MRI scan except for control HF subjects. These subjects with eGFR \\\u003C 30 ml\u002Fmin\u002F1.73 m2 will undergo MRI without gadolinium contrast.\n* Subjects on dialysis will be excluded\n* Pregnant state. For women in child bearing age, a urine pregnancy test will be performed prior to the PET and the cardiac MRI studies\n* Documented allergy to F-18 florbetapir, C-11 acetate or gadolinium.\n* Additional exclusion criteria for the active AL-CMP subjects: Subjects unable to return to BWH for 6 and 12 month clinical evaluation\n* Additional exclusion criteria for active AL-CMP-exercise subjects: Inability to exercise or return to BWH for C-11 acetate PET\u002FCT at baseline and 6 month clinical evaluations.\n* Additional exclusion criteria for active AL Pre-CMP- Inability to return to BWH 12 month clinical evaluation.\n\nAdditional exclusion criteria for microbiota study: Documented hypertrophic cardiomyopathy, HIV or chronic viral hepatitis, documented inflammatory bowel disease, systemic antibiotics, antivirals, antifungals or antiparasitic agents within 6 months, unable to mail the stool sample in a timely manner, bowel surgery, colon cancer, received chemotherapy, and pregnancy.","99 Years",{"count":411,"type":23},171,[334],"Cardiac amyloidosis is a major cause of early treatment-related death and poor overall survival in individuals with systemic light chain amyloidosis. This project will develop a novel approach to visualize cardiac amyloid deposits using advanced imaging methods. The long-term goal of this work is to identify the mechanisms of cardiac dysfunction, in order to guide the development of novel life-saving treatments.",[415,30],"Amyloidosis, Primary",[206,417,418,419],"F-18 florbetapir","Positron emission tomography","cardiac magnetic resonance imaging","2025-11-13",{"date":422,"type":45},"2025-11-14",{"date":424,"type":4},"2016-04-01",{"date":184,"type":23},{"name":427,"class":107},"Brigham and Women's Hospital",{"id":429,"slug":430,"hasResults":12,"nctId":431,"briefTitle":432,"officialTitle":432,"acronym":433,"eligibilityCriteria":434,"healthyVolunteers":12,"sex":18,"minAge":59,"maxAge":4,"enrollmentInfo":435,"targetDuration":4,"studyType":118,"phases":436,"briefSummary":438,"conditions":439,"keywords":445,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":454,"lastUpdatePostDateStruct":455,"startDateStruct":457,"completionDateStruct":459,"leadSponsor":461,"locationsCount":463},"100590211","phase-4-comparative-effectiveness-of-carvedilol-versus-metoprolol-succinate-in-heart-failure-patients-with-an-implantable-cardioverter-defibrillator-100590211","NCT06964464","Comparative Effectiveness of Carvedilol Versus Metoprolol Succinate in Heart Failure Patients With an Implantable Cardioverter Defibrillator","CARVTOP-ICD","Inclusion Criteria:\n\n* Age ≥ 18 years\n* ICD implanted for primary prevention for HFrEF (either ICM or NICM) with remote monitoring capability\n* Current treatment with metoprolol succinate and willing to switch to carvedilol\n* LVEF \\\u003C50% during the past 12 months prior to consent\n\nExclusion Criteria:\n\n* Unwilling or unable to follow the protocol\n* Treatment with any other ßB than metoprolol succinate or no ßB treatment\n* Known prior intolerance or contraindication to carvedilol\n* Systolic blood pressure \\\u003C100 mmHg\n* Enrollment in another clinical trial\n* Inability or unwilling to consent",{"count":166,"type":23},[437],"PHASE4","This prospective, multicenter, open-label, randomized comparative effectiveness trial, titled CARVTOP-ICD, evaluates the impact of carvedilol versus metoprolol succinate in patients with heart failure with reduced ejection fraction (HFrEF) and an implantable cardioverter defibrillator (ICD). The study will enroll 2,000 participants across 100 U.S. sites and includes an 18-month feasibility phase with 100 participants from 15 sites. Eligible participants must be currently treated with metoprolol succinate and willing to switch to carvedilol, with randomization in a 1:1 ratio. Participants will be followed for up to 3 years, with regular assessments including ICD interrogations, medication adherence, healthcare utilization, and quality of life surveys. The primary endpoint is the first occurrence of any ICD therapy (appropriate or inappropriate), cardiovascular (CV) hospitalization, or CV death. Secondary endpoints include ICD shock burden, healthcare utilization, and patient-reported quality of life. The trial aims to provide high-quality comparative data to address clinical equipoise surrounding the two commonly used beta-blockers in HFrEF management.",[440,441,442,443,444,30],"Heart Failure With Reduced Ejection Fraction (HFrEF)","Sudden Cardiac Death","Ventricular Arrhythmia","Implantable Cardioverter Defibrillator (ICD)","Beta-blocker Therapy",[446,447,448,449,450,451,452,453],"arrhythmia","heart failure","ICD","implantable cardioverter defibrillator","ICD shock","carvedilol","metoprolol succinate","beta-blocker","2025-09-12",{"date":456,"type":45},"2025-09-18",{"date":458,"type":45},"2025-08-17",{"date":460,"type":23},"2031-07-01",{"name":462,"class":107},"University of Rochester",13,{"id":465,"slug":466,"hasResults":12,"nctId":467,"briefTitle":468,"officialTitle":469,"acronym":4,"eligibilityCriteria":470,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":471,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":472,"conditions":473,"keywords":476,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":477,"lastUpdatePostDateStruct":478,"startDateStruct":480,"completionDateStruct":482,"leadSponsor":484,"locationsCount":76},"100068127","genetics-of-cardiovascular-and-neuromuscular-disease-100068127","NCT00138931","Genetics of Cardiovascular and Neuromuscular Disease","Genetic Studies of Patients and Their Families With Inherited Cardiovascular and Neuromuscular Diseases.","Inclusion Criteria:\n\n* Patients of all ages will be considered for the study. In particular, families with more than one affected relative will be sought.\n\nExclusion Criteria:\n\n* Subjects without a suspected inherited cardiovascular or neuromuscular disorder will be excluded from this study.",{"count":166,"type":23},"We are studying the genetics of human cardiovascular and neuromuscular disease. There are many different genetic regions that have been associated with the development of cardiomyopathy. An equal number of genetic regions have been associated with muscular dystrophy and there is overlap because some of the identical genes, when mutated, produce both cardiomyopathy and muscular dystrophy. We are working to identify genes and gene mutations associated with cardiomyopathy, arrhythmias and muscular dystrophy. We propose to screen these samples for mutations in genes known to be involved in these disorders.",[30,474,475],"Arrhythmia","Muscular Dystrophy",[30,474,475],"2025-09-05",{"date":479,"type":45},"2025-09-09",{"date":481,"type":4},"1996-09",{"date":483,"type":23},"2030-01",{"name":485,"class":107},"University of Chicago",{"id":487,"slug":488,"hasResults":12,"nctId":489,"briefTitle":490,"officialTitle":491,"acronym":4,"eligibilityCriteria":492,"healthyVolunteers":12,"sex":18,"minAge":59,"maxAge":493,"enrollmentInfo":494,"targetDuration":4,"studyType":118,"phases":495,"briefSummary":496,"conditions":497,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":504,"lastUpdatePostDateStruct":505,"startDateStruct":507,"completionDateStruct":509,"leadSponsor":511,"locationsCount":76},"100604810","community-exercise-treating-effect-on-cardiopulmonary-disease-patients-100604810","NCT07154355","Community Exercise Treating Effect on Cardiopulmonary Disease Patients","Clinical Study Protocol on the Impact of Community-Based Exercise Training on the Exercise Capacity of Patients With Reduced Cardiovascular and Pulmonary Function","Inclusion Criteria:\n\n1. Patients aged 18 to 85 with abnormal pulmonary or cardiovascular function.\n2. Individuals who have completed a medical screening form to confirm they are free from illnesses and prescription medications that could impair their ability to complete the required testing and fitness training.\n3. Participants who did not engage in structured, systematic moderate-to-intense strength or endurance training during the study period (specifically, not within the previous year).\n4. At the onset of the trial, participants were physically active but had never participated in formal exercise more than twice a week.\n\nExclusion Criteria:\n\n1. Patients with neuromuscular or skeletal disorders, or systemic diseases such as diabetes, cancer, or heart disease.\n2. Individuals using medications known to affect health or the interpretation of study results.\n3. Participants who have engaged in organized, systematic endurance or strength training of moderate to high intensity within the past year.\n4. Patients who decline to participate in the study.\n5. Other medical conditions or states that render exercise training inappropriate.","85 Years",{"count":364,"type":23},[334],"The goal of this clinical trial is to learn if community-based exercise training can benefit patients aged 18 to 85 with diminished cardiovascular and pulmonary function. The main aim of this study is:\n\n• Establish a community or home-based fitness training program for patients with cardiopulmonary insufficiency to improve adherence, safety, and efficacy while alleviating the burden on both patients and society.\n\nResearchers will compare community-based exercise training to non-exercise training to see if community-based exercise training works to improve cardiovascular and pulmonary function.\n\nParticipants will:\n\n* Engage in community or home exercise training for 40-60 minutes, five times weekly, during a duration of eight weeks. Exercise modalities are primarily determined by the patients' individual preferences and habits, such as brisk walking, running, swimming, cycling, and hiking.\n* Adjust the exercise intensity according to their cardiopulmonary exercise test and the person's perceived exertion level.\n* Utilize fitness bracelets or watches to document statistics during workouts and submit them to the experimenter weekly, covering the five days of exercise within that week.\n* refrain from making any dietary modifications throughout the trial.",[498,390,30,499,500,501,502,503],"Coronary Heart Disease (CHD)","COPD","Bronchial Asthma","Respiratory Failure","Thoracic Tumors","Cardiopulmonary Diseases","2025-08-26",{"date":506,"type":45},"2025-09-04",{"date":508,"type":45},"2025-01-30",{"date":510,"type":23},"2030-12",{"name":512,"class":107},"Guangdong Provincial People's Hospital",{"id":514,"slug":515,"hasResults":12,"nctId":516,"briefTitle":517,"officialTitle":518,"acronym":4,"eligibilityCriteria":519,"healthyVolunteers":17,"sex":18,"minAge":59,"maxAge":4,"enrollmentInfo":520,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":522,"conditions":523,"keywords":524,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":528,"lastUpdatePostDateStruct":529,"startDateStruct":531,"completionDateStruct":533,"leadSponsor":535,"locationsCount":76},"100577624","impella-reverse-remodeling-in-end-stage-heart-failure-100577624","NCT06800716","Impella Reverse Remodeling in End-Stage Heart Failure","A Prospective Study of Recovery Mechanisms in Heart Transplant Eligible Patients With Cardiogenic Shock on Impella 5.5 Support","Inclusion Criteria:\n\n* Age 18 years or older\n* Dilated cardiomyopathy (LVEDD \\> 5.5 cm and LVEF \\\u003C25%)\n* Indication for temporary mechanical circulatory support therapy with Impella 5.5 LVAD as a bridge to transplant or bridge to transplant decision based on treating physician's discretion\n\nExclusion Criteria:\n\n* Intra-aortic balloon pump (IABP) use for more than 7 days at the time of Impella 5.5 implantation\n* Percutaneous mechanical circulatory support device, extracorporeal membrane oxygenation (ECMO) or paracorporeal ventricular assist device (VAD) support prior to Impella 5.5 implantation\n* Congenital heart disease\n* Restrictive or hypertrophic Cardiomyopathy including hypertrophic obstructive cardiomyopathy (HOCM) Amyloidosis, and Sarcoidosis\n* Evidence of acute myocarditis by endomyocardial biopsy\n* Prior heart transplantation\n* Mechanical aortic \u002F mitral valve\n* Patient with known aortic diseases such as Marfan-Syndrome, Morbus Erdheim-Gsell or others\n* Left Ventricular thrombus\n* Left Ventricular rupture\n* Cardiac tamponade\n* Presence of an Atrial or Ventricular Septal Defect\n* Severe right ventricular (RV) Failure requiring mechanical RV support\n* Severe peripheral vascular disease precluding placement of the Impella System\n* Recent stroke resulting in significant neurological deficit\n* Hypercoagulable disease precluding device implantation\n* Severe thrombocytopenia (\\\u003C50,000)\n* Contraindication to anticoagulation\n* Suspected or known pregnancy or lactating women\n* Subject belongs to a vulnerable population",{"count":521,"type":23},50,"This observational study is being done to learn more about heart attack recovery in patients supported with the Impella 5.5 left ventricular assist device (LVAD) as part of their standard of care. There are three stages in this study: screening, treatment and post treatment. There will be two phases of enrollment: First phase will enroll 10 patients; second phase will enroll an additional 40 patients. Approximately 50 participants will take part in the study at Columbia University Irving Medical Center.\n\nParticipation in this research is expected to last approximately 14 months. This time estimate includes a screening period for about 1- 3 days, treatment period of 40 days and post treatment follow-up period for 1 year. Data will be collected through 1- year after heart transplant. Clinical data (medical history, vital signs, laboratory assessments) from medical records, to perform functional testing, and to obtain blood and discarded heart tissue fromfor the purpose of this research study.\n\nParticipants will be asked to share their records for echocardiography, right heart catheterization, laboratory data and clinical information. Participants are required to complete an assessment a 6-minute walk, and hand grip strength test.",[390,30],[525,526,527],"cardiogenic shock and transplant","impella","LVAD","2025-07-29",{"date":530,"type":45},"2025-07-31",{"date":532,"type":45},"2024-12-04",{"date":534,"type":23},"2027-11",{"name":536,"class":107},"Columbia University",{"id":538,"slug":539,"hasResults":12,"nctId":540,"briefTitle":541,"officialTitle":541,"acronym":4,"eligibilityCriteria":542,"healthyVolunteers":12,"sex":18,"minAge":543,"maxAge":544,"enrollmentInfo":545,"targetDuration":4,"studyType":118,"phases":547,"briefSummary":548,"conditions":549,"keywords":551,"overallStatus":212,"whyStopped":4,"lastUpdateSubmitDate":553,"lastUpdatePostDateStruct":554,"startDateStruct":556,"completionDateStruct":558,"leadSponsor":560,"locationsCount":76},"100597775","combined-effect-of-aerobic-and-resistance-exercise-in-non-ischemic-dilated-cardiomyopathy-patients-100597775","NCT07062874","Combined Effect of Aerobic and Resistance Exercise in Non Ischemic Dilated Cardiomyopathy Patients","Inclusion Criteria:\n\n* Both male and female Age 40 to 60\n* Left ventricular ejection fraction \\\u003C50%\n\nExclusion Criteria:\n\n* Patients diagnosed with valvular heart disease, supraventricular arrhythmias, congenital heart disease were excluded.\n* Neuromuscular diseases such as stroke, Parkinson.\n* Underlying pulmonary disease\n* Impaired cognitive function (14)","40 Years","60 Years",{"count":546,"type":23},66,[334],"This study explores the effects of combined aerobic and resistance exercise in patients with non-ischemic dilated cardiomyopathy (NIDCM). In a six-week randomized clinical trial with 66 participants, both exercise groups-combined and aerobic-only-showed significant improvements in exercise capacity, functional independence, dyspnea, and blood pressure. However, no significant difference was found between the two groups. The study concludes that both exercise approaches are effective, but longer studies are needed to determine if combined training offers added benefits.",[550],"CARDIOMYOPATHY",[552],"Cardiomyopathy, Dyspnea, Exercise, Functional Independence, NIDCM.","2025-07-11",{"date":555,"type":45},"2025-07-14",{"date":557,"type":23},"2025-07-28",{"date":559,"type":23},"2025-10-10",{"name":561,"class":107},"Riphah International University",{"id":563,"slug":564,"hasResults":12,"nctId":565,"briefTitle":566,"officialTitle":567,"acronym":4,"eligibilityCriteria":568,"healthyVolunteers":12,"sex":18,"minAge":59,"maxAge":4,"enrollmentInfo":569,"targetDuration":4,"studyType":118,"phases":571,"briefSummary":572,"conditions":573,"keywords":577,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":579,"lastUpdatePostDateStruct":580,"startDateStruct":582,"completionDateStruct":584,"leadSponsor":586,"locationsCount":76},"100587966","large-language-models-to-improve-the-quality-of-care-of-cardiology-patients-100587966","NCT06935253","Large Language Models To Improve the Quality of Care of Cardiology Patients","Towards Bridging Generalists to Subspecialists With Large Language Models","Inclusion Criteria:\n\n* Board certified or board eligible Cardiologist.\n\nExclusion Criteria:\n\n* Not currently practicing clinically",{"count":570,"type":23},12,[334],"This study evaluates the impact of large language models (LLMs) versus traditional decision support tools on clinical decision-making in cardiology. General cardiologists will be randomized to manage real patient cases from a cardiovascular genetic cardiomyopathy clinic, with or without AI assistance. Each case will be assessed by two cardiologists, and their responses will be graded by blinded subspecialty experts using a standardized evaluation rubric.",[574,30,575,576],"Hypertrophic Cardiomyopathy (HCM)","Genetic Disease","Cardiology",[578,576],"Large language models","2025-05-13",{"date":581,"type":45},"2025-05-15",{"date":583,"type":45},"2025-01-10",{"date":585,"type":23},"2025-12",{"name":587,"class":107},"Stanford University",{"id":589,"slug":590,"hasResults":12,"nctId":591,"briefTitle":592,"officialTitle":592,"acronym":4,"eligibilityCriteria":593,"healthyVolunteers":12,"sex":18,"minAge":594,"maxAge":4,"enrollmentInfo":595,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":597,"conditions":598,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":600,"lastUpdatePostDateStruct":601,"startDateStruct":602,"completionDateStruct":604,"leadSponsor":606,"locationsCount":76},"100588971","acquirement-of-clinical-and-genomic-data-to-diagnose-in-rare-inherited-cardiomyopathy-100588971","NCT06948344","Acquirement of Clinical and Genomic Data to Diagnose in Rare Inherited Cardiomyopathy","Inclusion Criteria:\n\npatients aged 19 years or older who have provided written consent for participation, have the capability to consent voluntarily and have been diagnosed with cardiomyopathy, as defined by one of the following criteria: -Ones with suspected genetic cardiomyopathy of unknown etiology, meeting at least one of the following conditions: i) Patients with idiopathic cardiomyopathy, for whom no clear secondary causes (e.g., history of hypertension, alcohol abuse, or chemotherapy) can be identified, and in whom a genetic etiology is strongly suspected.\n\nii) Patients who have previously undergone genetic testing using an NGS panel, but no pathogenic variants were identified, and further evaluation with whole genome sequencing (WGS) is warranted.\n\niii) Patients diagnosed with cardiomyopathy before the age of 50, without known contributing factors such as hypertension or excessive alcohol consumption, raising a strong suspicion of a genetic cause.\n\n-Patients with a family history of genetic cardiomyopathy, defined as having at least one first-degree relative (parent, sibling, or child) diagnosed with the same type of cardiomyopathy, confirming a familial genetic pattern.\n\nExclusion Criteria:\n\n* Patients with confirmed ischemic cardiomyopathy (when stenosis of 75% or more of major coronary arteries is confirmed on coronary artery imaging or ischemic cardiomyopathy findings such as transmural LGE on cardiac MRI)\n* Heart failure with other etiologies (e.g., valvular heart disease, endocrine disease)","19 Years",{"count":596,"type":23},560,"\"Background Information Cardiomyopathy is one of the leading causes of heart failure. In cases where cardiomyopathy does not respond to guideline-directed medical therapy for heart failure, the disease may progress to a stage where heart transplantation is the only viable treatment option. According to the 2022 Korean Organ Transplant Registry (KOTRY) report, cardiomyopathy accounted for approximately 65% of heart transplant indications in Korea, making it one of the most challenging unresolved issues in modern cardiology. Furthermore, cardiomyopathy is associated with a high risk of sudden cardiac death due to ventricular fibrillation or ventricular tachycardi and implantable cardioverter-defibrillators are often recommended as a preventive measure. Given that sudden cardiac death frequently occurs in young and middle-aged individuals, it is a major public health concern in developed countries such as North America and Western\u002FNorthern Europe, prompting ongoing societal and medical efforts to reduce its burden. The risk of sudden cardiac death imposes a persistent psychological burden on family members of patients with cardiomyopathy. Because sudden death can also occur in children and adolescents, current clinical guidelines recommend early cardiac evaluation and genetic counseling for family members of affected individuals.\n\nThis study seeks to overcome the current limitations in the genetic diagnosis of cardiomyopathy, including the low diagnostic yield of currently available gene panels. To date, most genetic data on cardiomyopathy have been derived from Western populations. There is a significant lack of population-specific genomic data for East Asians, particularly Koreans, making it difficult to interpret the results of genetic testing in Korean patients.\n\nBy developing bioinformatics algorithms that comprehensively analyze whole genome sequencing (WGS) data, including single nucleotide variants (SNVs), insertions\u002Fdeletions (indels), and structural variations, this study aims to generate a reference dataset tailored to the Korean population. This will directly improve the genetic diagnosis of cardiomyopathy in Korean patients. Additionally, by identifying novel pathogenic variants through WGS, this study may elucidate new disease mechanisms underlying cardiomyopathy. These findings could provide a theoretical basis for developing novel diagnostic biomarkers, therapeutic targets, and even gene-based therapies. The present study is part of a multi-phase national research project supported by the Korea Disease Control and Prevention Agency and the Korea National Institute of Health, conducted as a registry cohort titled the \"\"Korean Cardiomyopathy Cohort (KCC)\"\".\n\nObjectives This study aims to establish a diagnostic research framework to elucidate the genetic architecture of rare inherited cardiomyopathies through comprehensive analysis of whole genome sequencing data, with the goal of identifying novel diagnostic approaches",[30,599],"Whole Genome Sequencing","2025-05-12",{"date":579,"type":45},{"date":603,"type":45},"2023-10-10",{"date":605,"type":23},"2028-08-22",{"name":607,"class":107},"Yonsei University",{"id":609,"slug":610,"hasResults":12,"nctId":611,"briefTitle":612,"officialTitle":613,"acronym":614,"eligibilityCriteria":615,"healthyVolunteers":12,"sex":18,"minAge":59,"maxAge":4,"enrollmentInfo":616,"targetDuration":19,"studyType":24,"phases":4,"briefSummary":618,"conditions":619,"keywords":621,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":625,"lastUpdatePostDateStruct":626,"startDateStruct":628,"completionDateStruct":630,"leadSponsor":632,"locationsCount":634},"100584969","genetic-characterization-of-patients-with-arrhythmia-induced-cardiomyopathy-100584969","NCT06896266","Genetic Characterization of Patients With Arrhythmia-Induced Cardiomyopathy","Understanding and Characterizing the Genetics of Patients With Arrhythmia-Induced Cardiomyopathy","UNCHAINED-I","Inclusion Criteria:\n\n* Presence of atrial fibrillation or atrial flutter not self-limited.\n* Performance of a cardiac imaging test with systolic function analysis (echocardiogram, magnetic resonance, CT scan) during the clinical course of the arrhythmia, exhibiting a left ventricular ejection fraction (LVEF) \\\u003C50%. In order for the test to be representative, the maximum time between the performance of the imaging test and the rhythm control procedure will be 3 months, in the absence of intervening cardiovascular events that may have caused a variation in LVEF. In the event that the patient had a previously known LVEF \\\u003C50%, the change with respect to this attributable to tachyarrhythmia has to be ≥10%.\n* Signature of informed consent.\n* Ability to understand and accept participation in the study.\n\nExclusion Criteria:\n\n* Refusal of informed consent.\n* Legal or juridical incapacity.\n* Age \\\u003C18 years.\n* Life expectancy less than 1 year.\n* Impossibility of a follow-up of at least 6 months.\n* Presence of a ventricular rate \\>140 beats per minute, limiting the validity of imaging measurements.\n* Presence of known factors causing systolic ventricular dysfunction:\n\n  * Prior cardiomyopathy diagnosis.\n  * Severe mitral or aortic valve disease.\n  * Non-revascularizable ischemic heart disease.\n  * Context of peri-resuscitation cardiopulmonary care.\n  * Abusive alcohol consumption, defined as \\>80 grams of ethanol or \\>7 standard alcoholic beverages per day.\n  * Active treatment with chemotherapeutic agents or radiation therapy to the thorax.\n  * Known infection with Trypanosoma cruzi, Borrellia burgdorferi or other infectious agent causing cardiomyopathy.",{"count":617,"type":23},109,"The goal of this observational study is to learn about the genetic insights of arrhythmya-induced cardiomyopathy and its clinical prognosis. The main questions it aims to answer are:\n\nI. Does patients with arrhythmia-induced cardiomyopathy have a greater proportion of genetic mutations compared with other types of cardiomyopathy or general population? II. Have the genetics any prognostic impact in patients with arrhythmia-induced cardiomyopathy?",[474,30,620],"Arrhythmia-induced Cardiomyopathy (AiCM)",[622,623,447,624,94,238],"atrial fibrillation","atrial flutter","arrhythmia-induced cardiomyopathy","2025-05-09",{"date":627,"type":45},"2025-05-14",{"date":629,"type":45},"2024-12-01",{"date":631,"type":23},"2026-12",{"name":633,"class":107},"Hospital Universitario 12 de Octubre",4,{"id":636,"slug":637,"hasResults":12,"nctId":638,"briefTitle":639,"officialTitle":639,"acronym":640,"eligibilityCriteria":641,"healthyVolunteers":12,"sex":18,"minAge":59,"maxAge":409,"enrollmentInfo":642,"targetDuration":644,"studyType":24,"phases":4,"briefSummary":645,"conditions":646,"keywords":647,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":649,"lastUpdatePostDateStruct":650,"startDateStruct":652,"completionDateStruct":654,"leadSponsor":656,"locationsCount":76},"100582715","observational-epidemiological-study-of-patients-suffering-from-systemic-amyloidosis-100582715","NCT06866912","Observational Epidemiological Study of Patients Suffering From Systemic Amyloidosis","AMI-ER","Inclusion Criteria:\n\n* patients diagnosed with amyloidosis or asymptomatic carriers of mutations in the transthyretin gene\n* minimum age of 18 years at the time of diagnosis\n* obtaining informed consent\n\nExclusion Criteria:\n\n* nothing",{"count":643,"type":23},750,"10 Years","observational epidemiological study of patients affected by systemic amyloidosis",[30],[648],"Cardiac amyloidosis","2025-03-06",{"date":651,"type":45},"2025-03-10",{"date":653,"type":45},"2023-09-01",{"date":655,"type":23},"2033-08-31",{"name":657,"class":107},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",{"id":659,"slug":660,"hasResults":12,"nctId":661,"briefTitle":662,"officialTitle":663,"acronym":4,"eligibilityCriteria":664,"healthyVolunteers":12,"sex":18,"minAge":59,"maxAge":4,"enrollmentInfo":665,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":667,"conditions":668,"keywords":669,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":675,"lastUpdatePostDateStruct":676,"startDateStruct":678,"completionDateStruct":680,"leadSponsor":682,"locationsCount":76},"100490143","characterization-of-arrhythmia-induced-cardiomyopathy-100490143","NCT05662293","Characterization of Arrhythmia-induced Cardiomyopathy","Arrhythmia-induced Cardiomyopathy - a Prospective Observational Cohort Study","Prospective part\n\nInclusion Criteria:\n\n* Diagnostic or suspicion of AiCM as presence of specified keyword in patient's file or as screened by colleagues of the internal medicine or cardiology clinics\n* Signed study consent\n\nExclusion Criteria:\n\n* Patient's active refusal of the general consent of the University Hospital Basel\n* Age \\\u003C18 years old\n* Temporary exclusion criteria: Acute health condition such as myocardial infarction, patients presenting with a major trauma, a sepsis, patients shortly after cardiac surgery, and patients in shock (\\>100 bpm, \\\u003C90 systolic BP, evidence of organ dysfunction).\n* Life expectancy \\\u003C1 year (palliative, terminal cancer)\n\nRetrospective part\n\nInclusion Criteria:\n\n* Patients with a reduced left-ventricular ejection fraction (LVEF ≤50%) or a reduction of 15% in the ejection fraction (EF) between two echocardiographies and a concomitant diagnosis of any arrhythmia likely to lead to AiCM within one year before or after diagnosis of the reduced LVEF from 2010-2021\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years old\n* Patient's active refusal of the general consent of the University Hospital Basel\n* Acute event clearly leading to an acutely reduced LVEF (massive type I myocardial infarction, cardiogenic shock from a coronary or myocardial etiology, septic shock leading to toxic myopathy, hypovolemic shock with reduced EF, cardiac arrest and\u002For need for resuscitation).\n* Patients with life expectancy \\\u003C1 year (palliative, terminal cancer)",{"count":666,"type":23},2700,"The goal of the this observational study is to gather clinically available data on patients presenting with a suspicion for arrhythmia-induced cardiomyopathy (AiCM) at the University Hospital Basel.",[30,620],[670,671,672,623,673,674],"atrial fibrillation (AF)","supraventricular tachycardia (SVT)","ventricular tachycardia","Major Adverse Cardiovascular Event (MACE)","cardiac arrhythmia","2025-03-03",{"date":677,"type":45},"2025-03-04",{"date":679,"type":45},"2021-06-10",{"date":681,"type":23},"2027-01",{"name":683,"class":107},"University Hospital, Basel, Switzerland"]